FDA-approved
Digestive & weight
Tirzepatide
Evidence
FDA approved
Class
GIP and GLP-1 receptor agonist
KEY TAKEAWAY
Tirzepatide activates two gut hormone receptors, GIP and GLP-1. It is approved for type 2 diabetes and for chronic weight management. In a 72-week trial, adults on the highest dose lost about 20% of their body weight.
Written by the Veylo editorial team · Updated
November 2026
What it is
A dual GIP and GLP-1 receptor agonist
Approved for
Type 2 diabetes and chronic weight management in adults
Key fact
Produced about 20% weight loss at the top dose in a 72-week trial
Route
Weekly injection
Evidence strength
FDA approved
Tirzepatide is a once-weekly injectable peptide built from the GIP sequence with changes that let it also act on the GLP-1 receptor. It is sold as Mounjaro and Zepbound.
By acting on both GIP and GLP-1 receptors it increases insulin release after meals, slows digestion and reduces appetite. The combined action appears to lower blood sugar and body weight more than GLP-1 activation alone.
The FDA approved tirzepatide for type 2 diabetes in 2022 and for chronic weight management in 2023. Only the branded products are approved.
Glycemic control in type 2 diabetes and long-term weight management in adults with obesity or overweight and a related condition.
Nausea, diarrhea, vomiting and constipation are common and usually ease over time. Gallbladder disease and pancreatitis are possible. Like semaglutide, the label includes a boxed warning about thyroid C-cell tumors in rodents.
Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.